Holen Sie sich die Stockscreener-App
9.98
2.35%
-0.24
Handel nachbörslich:
9.97
-0.010
-0.10%
Telix Pharmaceuticals Ltd Adr Aktie (TLX) Neueste Nachrichten
Study Tests Imaging to Select Patients for Telix Prostate Therapy - Stock Titan
ETFs Investing in Telix Pharmaceuticals Limited Sponsored ADR Stocks - TradingView
Telix Pharmaceuticals (TLX) hits US$247M Q2, inks Regeneron deal - Stock Titan
Telix Pharmaceuticals (ASX:TLX) Targets More Than US$1 Billion in Revenue and Other Income After Quarterly Revenue Jumps 21% - Kalkine
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - GlobeNewswire Inc.
Telix Starts Phase 3 Targeted Radiation Study for Kidney Cancer - Stock Titan
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - Sahm
Telix Tests Targeted Therapy Earlier in Metastatic Prostate Cancer - Stock Titan
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on FDA trial progress - Investing.com
Telix Pharmaceuticals (ASX:TLX): The Nuclear Medicine Company Attracting Significant Investor Attention - Kalkine
Telix Pharmaceuticals (ASX:TLX): Radiopharmaceutical Innovator Pauses in a Rising Sector - Kalkine
FDA backs Telix (NASDAQ: TLX) ProstACT Global Phase 3 trial design - Stock Titan
Telix Pharmaceuticals (ASX:TLX) in Focus After Positive U.S. Regulatory Update - Kalkine
Telix clears FDA protocol review for prostate cancer trial expansion - Stock Titan
Telix Pharmaceuticals Limited Sponsored ADR Actuals & Estimates (NASDAQ:TLX) - TradingView
Telix webinar spotlights glioblastoma care and theranostics next week - Stock Titan
ASX Healthcare Sector Rally: CSL, ResMed and Telix Advance on Broad Market Strength - Kalkine
AI-enhanced cancer scans: Telix and United Imaging team up on theranostics - Stock Titan
Telix CEO lines up back-to-back investor talks in Chicago and New York - Stock Titan
TLXTelix Pharmaceuticals Ltd ADR Stock Price and Quote - Finviz
TLX SEC FilingsTelix Pharmaceuticals Ltd ADR 10-K, 10-Q, 8-K Forms - Stock Titan
Telix Pharmaceuticals Ltd stock (AU000000TLX2): FDA filing advances - Ad-hoc-news.de
Telix Pharmaceuticals (TLX) furnishes AGM addresses, presentation and results via Form 6-K - Stock Titan
Telix Pharmaceuticals (TLX) director Form 3 shows no share trades - Stock Titan
Telix Pharmaceuticals (TLX) director Jellison files initial Form 3 ownership - Stock Titan
Maria Rivas joins Telix Pharmaceuticals (TLX) board and files initial Form 3 - Stock Titan
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches - Sahm
Can Telix Pharmaceuticals (ASX:TLX) Regain Momentum Ahead of Key FDA Decision? - Kalkine
Telix (TLX) CEO boosts indirect stake with 67,935-share open-market buy - Stock Titan
Kidney cancer scan showed 98% positive predictive value in analysis - Stock Titan
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating at buy - Investing.com
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach - Sahm
US$600M Telix Pharmaceuticals (TLX) convertible bond settlement noted - Stock Titan
TLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Telix Pharmaceuticals (TLX) files 6-K on AGM and proxy materials - Stock Titan
Telix’s Phase 3 prostate cancer study gets a late-breaking ASCO slot - Stock Titan
[6-K] Telix Pharmaceuticals Ltd Current Report (Foreign Issuer) | TLX SEC FilingForm 6-K - Stock Titan
Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs - Sahm
First radiopharmaceutical enters Phase 3 for recurrent brain cancer - Stock Titan
Regeneron taps Telix in $40M push for next-generation cancer drugs - Stock Titan
Telix Pharmaceuticals stock gains on FDA acceptance of NDA - Investing.com
Telix Pharmaceuticals stock gains on FDA acceptance of NDA By Investing.com - Investing.com South Africa
Revenue growth on track for undervalued ASX healthcare stock - Morningstar Australia
Brain cancer imaging agent moves toward FDA decision by Sept. 11 - Stock Titan
Former Pfizer and Stryker leaders join Telix board expansion - Stock Titan
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on revenue growth - Investing.com
Telix Appoints David Gill as Non-Executive Director - Sahm
[Form 4] Telix Pharmaceuticals Ltd Insider Trading Activity - Stock Titan
Telix Pharmaceuticals (TLX) director discloses 3.63M indirect shares - Stock Titan
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):